Dave Kappos Moderates Panel at 2019 WIPO Symposium on Trade Secrets and Innovation
December 02, 2019
Cravath partner David J. Kappos participated in the World Intellectual Property Organization’s 2019 “Symposium on Trade Secrets and Innovation,” held in Geneva from November 25‑26, 2019. Dave moderated a panel entitled “Trade Secret Systems in Innovation, Intellectual Property Policies and Development,” which discussed how a range of policy issues including relating to artificial intelligence and blockchain are relevant to the development of trade secret protection globally.
Dave also spoke on a panel entitled “Navigating Trade Secret Systems in the Changing Innovation Environment,” which discussed the characteristics of trade secret protection and how trade secrets fit into the global innovation landscape.
Related Practices & Industries
Speakers
- Photo
-
-
J.D., 1990, University of California, Berkeley, School of Law
-
B.S., 1983, University of California, Davissumma cum laude
- New York
- California
- District of Columbia
Education
Admitted In
Related News & Insights
Deals & Cases
November 24, 2019
AP WIP Investments Holdings, LP’s Acquisition by Landscape Acquisition Holdings Limited
On November 19, 2019, Landscape Acquisitions Holdings Limited (“Landscape”) announced that it has entered into a definitive agreement to acquire AP WIP Investments Holdings, LP, one of the largest global aggregators of real property interests underlying wireless telecommunications cell sites, for consideration of approximately $860 million consisting of cash, shares and assumption of debt. Cravath is representing AP WIP Investments Holdings, LP in connection with the transaction.
Deals & Cases
November 01, 2019
Roivant and Sumitomo Dainippon Pharma’s Strategic Alliance
On October 31, 2019, Roivant Sciences Ltd. (“Roivant”), a technology‑enabled healthcare company, and Sumitomo Dainippon Pharma Co., Ltd. (“Sumitimo Dainippon Pharma”), a leading Japanese pharmaceutical company, announced they have signed a definitive agreement for the creation of a novel and broad strategic alliance to form a new company owned and supported by Sumitomo Dainippon Pharma.
Deals & Cases
September 30, 2019
Sobi’s Acquisition of Dova
On September 30, 2019, Swedish Orphan Biovitrum AB (publ) (“Sobi”), an international biopharmaceutical company that provides access to innovative therapies for people affected by rare diseases, announced a definitive agreement to acquire Dova Pharmaceuticals, Inc. (“Dova”), maker of Doptelet, used for the treatment of thrombocytopenia. The transaction is valued at up $915 million on a fully diluted basis. Cravath is representing Sobi in connection with the transaction.
Deals & Cases
August 29, 2019
Disney’s $3.47 Billion Sale of Its Interest in the YES Network to Investor Group Including the Yankees and Sinclair
On August 29, 2019, The Walt Disney Company (“Disney”) announced that it has sold its equity interest in the YES Network to a newly formed investor group that includes Yankee Global Enterprises (the “Yankees”) and Sinclair Broadcast Group (“Sinclair”), among others. The group acquired the 80 percent of the YES Network not already held by the Yankees at a total enterprise value of $3.47 billion. Cravath represented Disney in connection with the transaction.
